dinitrochlorobenzene may decrease hiv viral burden

1
RESEARCH & DEVELOPMENT Dinitrochlorobenzene may decrease HIV viral burden Topical dinitrochlorobenzene (DNCB) may help to decrease viral burden in patients with HIV infection, say US researchers. Dinitrochlorobenzene is believed to stimulate cell-mediated immune function when applied to the skin, they explain. They evaluated 8 HIV-infected patients, 5 of whom were asymptomatic, I with AIDS-related complex and 2 with AIDS. The patients were not using anti- retroviral therapy during the study period. They received 3-4 months' topical dinitrochlorobenzene therapy, starting with an initial sensitisation by applying a solution of 10% DNCB to the forearm. All patients showed contact dermatitis after sensitisation. Two weeks later, patients started therapy with weekly 2% DNCB, applied to a different part of the trunk or the extremities each week. Six further patients with HIV infection served as controls. After 3-4 months' therapy, mean plasma HIV RNA levels had declined significantly in the DNCB-treated patients, while the control patients had a significant increase in mean plasma HIV RNA levels, say the researchers. All patients remained clinically stable during the study period and there were no major adverse effects associated with DNCB therapy, they add. Stricker RB, Goldberg B, Mills LB, Epstein WL. Decrease in viral load associated with topical diniuochlorobenzcne therapy in mv disease. Researc:hin Virology 148: 343-348, Sep-Oct 1997 IlOO66236II Adl. Im.m.tIolIIIl LlmIlecl1"7. All rlglQ rwerwd 11 Inphenna- 20 Dec 18117 No. 1118

Post on 12-Dec-2016

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Dinitrochlorobenzene may decrease HIV viral burden

RESEARCH & DEVELOPMENT

Dinitrochlorobenzene may decrease HIV viral burden

Topical dinitrochlorobenzene (DNCB) may help to decrease viral burden in patients with HIV infection, say US researchers. Dinitrochlorobenzene is believed to stimulate cell-mediated immune function when applied to the skin, they explain.

They evaluated 8 HIV-infected patients, 5 of whom were asymptomatic, I with AIDS-related complex and 2 with AIDS. The patients were not using anti-retroviral therapy during the study period. They received 3-4 months' topical dinitrochlorobenzene therapy, starting with an initial sensitisation by applying a solution of 10% DNCB to the forearm. All patients showed contact dermatitis after sensitisation. Two weeks later, patients started therapy with weekly 2% DNCB, applied to a different part of the trunk or the extremities each week. Six further patients with HIV infection served as controls.

After 3-4 months' therapy, mean plasma HIV RNA levels had declined significantly in the DNCB-treated patients, while the control patients had a significant increase in mean plasma HIV RNA levels, say the researchers. All patients remained clinically stable during the study period and there were no major adverse effects associated with DNCB therapy, they add. Stricker RB, Goldberg B, Mills LB, Epstein WL. Decrease in viral load associated with topical diniuochlorobenzcne therapy in mv disease. Researc:hin Virology 148: 343-348, Sep-Oct 1997 IlOO66236II

11~4I9711118-000111$01 .000 Adl. Im.m.tIolIIIl LlmIlecl1"7. All rlglQ rwerwd

11

Inphenna- 20 Dec 18117 No. 1118